Immunic, inc. announces first psoriasis patient enrolled in ongoing phase 1 trial of imu-935

New york, oct. 27, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first psoriasis patient in part c of its ongoing phase 1 clinical trial of imu-935, a highly potent and selective inverse agonist of the transcription factor rorΓt. part c is structured as a 28-day, double-blind, placebo-controlled trial designed to enroll approximately 52 patients, randomized 3:1 versus placebo with two treatment cohorts.
IMUX Ratings Summary
IMUX Quant Ranking